Bravo, Isabel M Luster, Brennon R Flanigan, Meghan E Perez, Patric J Cogan, Elizabeth S Schmidt, Karl T McElligott, Zoe A
Published in
The European journal of neuroscience
Persons suffering from opioid use disorder (OUD) experience long-lasting dysphoric symptoms well into extended periods of withdrawal. This protracted withdrawal syndrome is notably characterized by heightened anxiety and hyperkatifeia. Here, we investigated if an exacerbated withdrawal model of acute morphine dependence results in lasting behaviora...
Klein, Lauren R Cole, Jon B Driver, Brian E Miner, James R Laes, JoAn R Fagerstrom, Erik L Martel, Marc
Published in
Clinical toxicology (Philadelphia, Pa.)
Background: Patients with opioid withdrawal often present to the Emergency Department (ED), but many EDs do not have the infrastructure in place to initiate treatment with opioid agonists (methadone or buprenorphine). Therefore, ED management often entails symptomatic control. The purpose of this study was to compare olanzapine to clonidine for the...
Doughty, Bennett Morgenson, Daralyn Brooks, Tracy
Published in
The Annals of pharmacotherapy
To review the pharmacology, efficacy, and safety of lofexidine for the treatment of opioid withdrawal secondary to the recent Food and Drug Administration (FDA) approval. A literature search using PubMed was conducted (inception to December 2018) using the terms lofexidine, opioid, opiate, and withdrawal. References from retrieved articles and the ...
Ward, Heather Burrell Barnett, Brian S Suzuki, Joji
Published in
Substance abuse
Patients taking methadone for opioid use disorder may desire transition to buprenorphine for a number of reasons. However, the current recommended approach for this transition generally takes weeks to months as an outpatient, causing considerable discomfort to the patient and a heightened risk of relapse during the transition period. We describe th...
Zavod, Abigail Akerman, Sarah C Snow, Martha M Tierney, Matt Sullivan, Maria A
Published in
Journal of the American Psychiatric Nurses Association
BACKGROUND: The United States is experiencing an opioid epidemic. Better approaches to encourage outpatient utilization of Food and Drug Administration-approved medications for the treatment of opioid use disorder, including extended-release naltrexone (XR-NTX), are needed. Withdrawal management before initiation of XR-NTX is challenging for clinic...
Noller, Geoffrey E Frampton, Chris M Yazar-Klosinski, Berra
Published in
The American journal of drug and alcohol abuse
The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. To examine longitudinal treatment effects over a 12-month period among individuals receiving legal ibogaine t...
Ohler, Kirsten H Pham, Jennifer T
Published in
Pharmacotherapy
Burma, Nicole E Leduc-Pessah, Heather Trang, Tuan
Published in
Channels (Austin, Tex.)
Opioids are among the most powerful analgesics for managing pain, yet their repeated use can lead to the development of severe adverse effects. In a recent study, we identified the microglial pannexin-1 channel (Panx1) as a critical substrate for opioid withdrawal. Here, we investigated whether microglial Panx1 contributes to opioid-induced hyperal...
Nikolaou, Kakia Kapoukranidou, Dorothea Ndungu, Samuel Floros, Georgios Kovatsi, Leda
Published in
Journal of psychoactive drugs
Pre-clinical studies show that, following chronic opioid exposure, oxytocin neurons exhibit over-excitation upon withdrawal, causing an increase in oxytocin brain and plasma levels. Relevant clinical data on humans are scarce. This study investigates the opioid withdrawal stress effect on oxytocin plasma levels in humans. We evaluated 57 male chron...
Raj, B Neeraj Manamohan, N Hegde, Divya Huded, Chandrashekar B Pradeep, Johnson
Published in
Indian journal of psychological medicine
Opioids are one of the commonly abused substances in India. Opioid withdrawal symptoms classically include severe muscle cramps, bone aches, autonomic symptoms, anxiety, restlessness, insomnia, and temperature dysregulation. However, reports of cases with delirium during withdrawal are few. A 25-year-old male with severe opioid withdrawal symptoms ...
